top of page

Clinical Advisory Board

Jacob M. Rowe, MD Chairman

Dr. Rowe is former Chief, Department of Hematology and Bone Marrow Transplantation at Rambam Medical Center and Dresner Professor of Hemato-oncology, Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, in Haifa, Israel. He is also Adjunct Professor of Medicine in the Department of Medicine at Northwestern University in Chicago, Illinois. Dr. Rowe received a Bachelor of Medicine degree from the University College Hospital Medical School in London and subsequently trained in London, Israel, and the United States. Dr. Rowe’s work focuses on the development of new treatment modalities for patients with hematologic malignancies. Dr. Rowe is Editor-in-Chief of Baillieres Best Practice & Research: Clinical Hematology, Co-Editor of Blood Reviews, and Section Editor of Leukemia. He is also on the editorial boards of the American Journal of Hematology, Blood, Clinical Leukemia, and Leukemia Research. He has chaired 5 and currently is chairing 2 Eastern Cooperative Oncology Group (ECOG) clinical studies. Among other organizations, Dr. Rowe is a fellow of the American College of Physicians and a member of the American Society of Hematology, American Society of Clinical Oncology, European Bone Marrow Transplant Group, and National Oncology Council, Israel. Dr. Rowe has presented more than 
230 abstracts at major national and international meetings and has published more than 240 journal articles and book chapters.

Martin S. Tallman, MD

Dr.  Tallman is Chief, Leukemia Service at Memorial Sloan-Kettering Cancer Center and Professor of Medicine at Weill Cornell Medical College in New York, USA.   He is a diplomate of the American Board of Internal Medicine with sub-specialty certification in the areas of hematology and medical oncology.  He served as Chair of the Leukemia Committee of the Eastern Cooperative Oncology Group for 16 years.  

Dr. Tallman is a member of numerous committees of national, regional, and international professional societies involved in the study and treatment of cancer, including the American Society of Hematology, American Society of Clinical Oncology, the Eastern Cooperative Oncology Group, the International Society of Thrombosis and Haemostasis, and the American Association for Cancer Research.  He serves as Co-Chair of the on the Acute Myeloid Leukemia Panel of the National Comprehensive Cancer Network (NCCN).  He is a fellow of the American College of Physicians. Dr. Tallman recently completed two terms as an Associate Editor of Blood.  He is a reviewer for many professional publications.

Dr. Tallman received his bachelor’s degree in Science at the University of Michigan in Ann Arbor, Michigan, USA and his medical degree at Finch University of Health Sciences/The Chicago Medical School in Chicago, Illinois, USA. 


Pierre Fenaux, MD, PhD

Dr. Fenaux is a Professor of Hematology, the founder and Head of the section of myeloid malignancies in the elderly at hôpital Saint Louis in Paris. Dr Fenaux is also part of Inserm research unit at Hôpital St Louis, Paris, for his laboratory research activity, where he is involved in translational research in the field of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Dr. Fenaux is also a founding member and Chairman of the French MDS group (Groupe Francophone des Myélodysplasies, GFM), and of the French AML-APL group (GT-LAP). In addition to the coordination of clinical trials in MDS and APL, through the GFM and GT-LAP, respectively, Dr. Fenaux’s laboratory research is currently focused on the analysis of drug mechanism of action in MDS and AML, on development of murine models of MDS/AML and on mechanisms of resistance to treatment in AML-APL.

Selina M. Luger, MD

Selina M. Luger, MD, FRCPC is a Professor of Medicine at the Hospital of the University of Pennsylvania. Dr. Luger is a clinical researcher hematologic malignancies, leukemia, AML, ALL, CML, myelodysplastic syndrome, MDS, myeloproliferative disorders, stem cell transplantation, bone marrow transplant.

Eytan M. Stein, MD

Eytan M. Stein, MD is an Assistant Attending Physician, Clinical Investigator and Director of the Program for Drug Development in Leukemia on the Leukemia Service at Memorial Sloan Kettering Cancer Center. Dr, Stein conducts novel, phase I clinical trials of compounds that target the genetic and epigenetic basis of myeloid malignancies. Dr. Stein led the clinical studies of the IDH2 inhibitor Enasidenib and the IDH1 Inhibitor Ivosidenib in patients with relapsed and refractory AML that led to their FDA approval in 2017 and 2018, respectively. He also leads a variety of phase 1 clinical trials and serves as the lead investigator at Memorial Sloan Kettering for the BEAT AML master clinical trial. His current research focuses on elucidating mechanisms of resistance to IDH inhibitors and the use of Menin inhibitors in patients with MLL-rearranged acute leukemia. His work has been published in journals such as Nature, Nature Medicine, The New England Journal of Medicine, JAMA Oncology, Cancer Discovery and Blood. In addition, he serves on the Editorial Boards of Blood and Leukemia and Lymphoma.


Tsila Zuckerman, MD

Dr. Zuckerman is the Head of the Bone Marrow Transplantation Unit at Rambam Campus, Technion, Haifa, Israel. Dr. Zuckerman received her MD degree from the Faculty of Medicine of the Technion-Israel Institute of Technology. She completed Fellowships in Internal Medicine at the Carmel Medical Center, and in Hematology and Bone Marrow Transplantation at the University of Southern California, USA.

Dr. Zuckerman serves as coordinator of the Integrative Course in Hemato-Oncology at the Faculty of Medicine of the Technion. She is co-author of about 20 scientific articles, published in the leading international journals in the field of hematology, and is a presenter at major national and international meetings.   Her main research interests are the correlation between hepatitis C virus and development of lymphoma; complications of bone marrow transplantation including Veno-Occlusive Disease (VOD) and infections; and minimal residual disease in leukemia patients.

bottom of page